Advanced age is the primary risk factor for Parkinson's disease (PD). In PD patients and rodent models of PD, advanced age is associated with inferior symptomatic benefit following intrastriatal grafting of embryonic dopamine (DA) neurons, a pattern believed to result from decreased survival and reinnervation provided by grafted neurons in the aged host. To help understand the capacity of the aged, parkinsonian striatum to be remodeled with new DA terminals, we used a grafting model and examined whether increasing the number of grafted DA neurons in aged rats would translate to enhanced behavioral recovery. Young (3 months), middle-aged (15 months), and aged (22 months) parkinsonian rats were grafted with proportionately increasing numbers of embryonic ventral mesencephalic (VM) cells to evaluate whether the limitations of the graft environment in subjects of advancing age can be offset by increased numbers of transplanted neurons. Despite robust survival of grafted neurons in aged rats, reinnervation of striatal neurons remained inferior and amelioration of levodopa-induced dyskinesias (LID) was delayed or absent. This study demonstrates that: 1) counter to previous evidence, under certain conditions the aged striatum can support robust survival of grafted DA neurons; and 2) unknown factors associated with the aged striatum result in inferior integration of graft and host, and continue to present obstacles to full therapeutic efficacy of DA cell-based therapy in this model of aging.
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Introduction
The therapeutic potential of dopamine (DA) neuron grafts in patients with Parkinson's disease (PD) has been variable and remains controversial and incompletely understood. Despite a moratorium on clinical grafting in PD over the previous decade, a critical reappraisal of preclinical and clinical transplantation data has lead to a limited renewal of clinical trials (Evans et al., 2012; Barker et al., 2013; ClinicalTrials.gov NCT01898390) . This, together with continuing interest in stem cell-based replacement strategies (Ambasudhan et al., 2014; Buttery and Barker, 2014; Sundberg and Isacson, 2014) and trophic factor-induction of nigral DA terminal re-growth (Kordower and Bjorklund, 2013; Hickey and Stacy, 2013) , highlights the importance of understanding the capacity and limitations of repairing the parkinsonian striatum. In addition to implications for clinical application of DA neuron grafting, cell transplantation is a valuable approach for interrogating the nature of the environment of the aged brain as it permits or discourages integration of new elements intended to facilitate restoration and repair. The presence of grafted cells, in effect, reveals characteristics of the environment through their attempts to survive, grow, and integrate with the host brain.
While clinical and preclinical data support the idea that DA neuron transplantation into the striatum is most effective in younger individuals (Collier et al., 1999; Freed et al., 2001; Sortwell et al., 2001 ) with less severe DA-depletion (Breysse et al., 2007; Piccini et al., 2005) , clinical grafting trials to date have enrolled primarily patients with advanced PD that were not benefiting from standard medical therapy (Evans et al., 2012; Kefalopoulou et al., 2011; Ma et al., 2011) . The rationale for choosing this population of patients is valid in that these individuals represent the population most in need of alternative therapeutics; nevertheless, the impact of factors associated with the Neurobiology of Disease 77 (2015) 191-203 
